Clinical Trial Update: Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating autologous cytokine-induced killer (CIK) cells for patients with Chronic Myeloid Leukemia on standard drug therapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Autologous Cytokine Induced Killer Cells (CIK) therapy (cytokine-induced killer cells)

Snippet

Sponsor: Singapore General Hospital | Conditions: Chronic Myeloid Leukemia | Phase 2 | Status: COMPLETED